Sara Becerril

Dr. Sara Becerril

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
GFGema Frühbeck
Gema Frühbeck
Victoria CatalánVictoria Catalán
Victoria Catalán
ARAmaia Rodríguez
Amaia Rodríguez
BRBeatriz Ramírez
Beatriz Ramírez
SBSara Becerril
Sara Becerril
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
Obesity favors the development of cardiometabolic alterations such as type 2 diabetes (T2D) and the metabolic syndrome (MS). Obesity and the MS are distinguished by an increase in circulating leptin concentrations, in parallel to a drop in the levels of adiponectin. Consequently, the Adpn/Lep ratio has been suggested as a maker of dysfunctional adipose tissue. We aimed to investigate in humans (n = 292) the reliability of the Adpn/Lep ratio as a biomarker of adipose tissue dysfunction. We considered that an Adpn/Lep ratio of ≥1.0 can be considered normal, a ratio of ≥0.5 <1.0 suggests moderate-medium increased risk, and a ratio of <0.5 indicates a severe increase in cardiometabolic risk. Using these cut-offs, 5%, 54% and 48% of the lean, normoglycemic and without-MS subjects, respectively, fall within the group with an Adpn/Lep ratio below 0.5; while 89%, 86% and 90% of the obese, with T2D and with MS patients fall within the same group (p < 0.001). A significant negative correlation (r = −0.21, p = 0.005) between the Adpn/Lep ratio and serum amyloid A (SAA) concentrations, a marker of adipose tissue dysfunction, was found. We concluded that the Adpn/Lep ratio is a good indicator of a dysfunctional adipose tissue that may be a useful estimator of obesity- and MS-associated cardiometabolic risk, allowing the identification of a higher number of subjects at risk.

15 October 2015 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
ARAmaia Rodríguez
Amaia Rodríguez
SESilvia Ezquerro
Silvia Ezquerro
LMLeire Méndez-Giménez
Leire Méndez-Giménez
SBSara Becerril
Sara Becerril
GFGema Frühbeck
Gema Frühbeck
Adipose tissue constitutes an extremely active endocrine organ with a network of signaling pathways enabling the organism to adapt to a wide range of different metabolic challenges, such as starvation, stress, infection, and short periods of gross energy excess. The functional pleiotropism of adipose tissue relies on its ability to synthesize and release a huge variety of hormones, cytokines, complement and growth factors, extracellular matrix proteins, and vasoactive factors, collectively termed adipokines. Obesity is associated with adipose tissue dysfunction leading to the onset of several pathologies including type 2 diabetes, dyslipidemia, nonalcoholic fatty liver, or hypertension, among others. The mechanisms underlying the development of obesity and its associated comorbidities include the hypertrophy and/or hyperplasia of adipocytes, adipose tissue inflammation, impaired extracellular matrix remodeling, and fibrosis together with an altered secretion of adipokines. Recently, the potential role of brown and beige adipose tissue in the protection against obesity has been also recognized. In contrast to white adipocytes, which store energy in the form of fat, brown and beige fat cells display energy-dissipating capacity through the promotion of triacylglycerol clearance, glucose disposal, and generation of heat for thermogenesis. Identification of the morphological and molecular changes in white, beige, and brown adipose tissue during weight gain is of utmost relevance for the identification of pharmacological targets for the treatment of obesity and its associated metabolic diseases.

24 February 2009 in International Journal of Obesity
Verified
Journal Article
Closed access
ARAmaia Rodríguez
Amaia Rodríguez
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
Victoria CatalánVictoria Catalán
Victoria Catalán
MGM J Gil
M J Gil
SBSara Becerril
Sara Becerril
GFGema Frühbeck
Gema Frühbeck

20 April 2016 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
ARAmaia Rodríguez
Amaia Rodríguez
SBSara Becerril
Sara Becerril
SESilvia Ezquerro
Silvia Ezquerro
LMLeire Méndez‐Giménez
Leire Méndez‐Giménez
GFGema Frühbeck
Gema Frühbeck

1 August 2009 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
GFGema Frühbeck
Gema Frühbeck
SBSara Becerril
Sara Becerril
NSNeira Sáinz
Neira Sáinz
PGPuy Garrastachu
Puy Garrastachu
MGMaria Garcia-Velloso
Maria Garcia-Velloso

4 September 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNeira Sáinz
Neira Sáinz
ARAmaia Rodríguez
Amaia Rodríguez
Victoria CatalánVictoria Catalán
Victoria Catalán
SBSara Becerril
Sara Becerril
BRBeatriz Ramírez
Beatriz Ramírez
GFGema Frühbeck
Gema Frühbeck
Absence of leptin has been associated with reduced skeletal muscle mass in leptin-deficient ob/ob mice. The aim of our study was to examine the effect of leptin on the catabolic and anabolic pathways regulating muscle mass. Gastrocnemius, extensor digitorum longus and soleus muscle mass as well as fiber size were significantly lower in ob/ob mice compared to wild type littermates, being significantly increased by leptin administration (P<0.001). This effect was associated with an inactivation of the muscle atrophy-related transcription factor forkhead box class O3 (FoxO3a) (P<0.05), and with a decrease in the protein expression levels of the E3 ubiquitin-ligases muscle atrophy F-box (MAFbx) (P<0.05) and muscle RING finger 1 (MuRF1) (P<0.05). Moreover, leptin increased (P<0.01) protein expression levels of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), a regulator of muscle fiber type, and decreased (P<0.05) myostatin protein, a negative regulator of muscle growth. Leptin administration also activated (P<0.01) the regulators of cell cycle progression proliferating cell nuclear antigen (PCNA) and cyclin D1, and increased (P<0.01) myofibrillar protein troponin T. The present study provides evidence that leptin treatment may increase muscle mass of ob/ob mice by inhibiting myofibrillar protein degradation as well as enhancing muscle cell proliferation.